ACE2 Effector Reporter Cells
|Coronavirus disease 2019 (COVID-19) increases the risk of developing Acute Respiratory Distress Syndrome (ARDS), which is often fatal at the late stages of the infection when the SAR-CoV-2 virus causes significant damage to the lungs. As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein receptor binding domain (RBD) recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells.|
Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection.
|Stability:||32 passages(in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Freeze Medium:||90% FBS+10% DMSO|
|Application(s):||This kit is useful for screening for inhibitors of ACE2 binding to SARS-CoV-2 Spike RBD.|
|Synonym(s):||covid, covid-19, covid19, coronavirus, ACE2 inhibitor kit, Spike RBD Inhibition kit, ACE2 colorimetric kit, SARS-CoV-2 assay kit|
|Storage:||Up to 6 months from date of receipt, when stored as recommended|
|IV. Representative Data|
Figure 1. Dose Response of SARS-CoV-2 Spike Proteins in Human ACE2 Effector Reporter Cells (C2).
Figure 2. Inhibition of SARS-CoV-2 Spike Proteins induced Reporter Activity in ACE2 Effector Reporter Cells.